'$ICPT — Anyone else disappointed w/ this morning's NASH study update? Not much new to chew over. The per protocol efficacy results seem like marketing material. Safety data essentially same as previously disclosed. Am I missing something?' -STAT's Adam F
Benzinga Newsdesk